SELECT PUBLICATIONS

André T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract

Cassidy J et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): Efficacy results of a phase III trial. Proc ASCO 2004;Abstract 3509.

De Gramont A et al. Oxaliplatin/5FU/LV in the adjuvant treatment of Stage II and Stage III colon cancer: Efficacy results with a median follow-up of 4 years. Proc ASCO 2005;Abstract 3501.

De Gramont A et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer. Proc ASCO 2004;Abstract 3525.

De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc ASCO 2003;Abstract 1015.

Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol 2005;23(15):3311-3. No abstract available

Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003;30(4 Suppl 15):5-13. Abstract

Saltz LB et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/ irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO GI Cancer Symposium 2005;Abstract 169b.

Twelves C et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer. Proc ASCO 2005a;Abstract 3521.

Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005b;352(26):2696-704. Abstract

Wolmark N et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP protocol C-07. Proc ASCO 2005;Abstract 3500.